Autopsy report · NCT04660084
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
Cause of deathOther
“The trial was stopped earlier than planned after an ad hoc interim analysis”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 1 year 9 months before it stopped.
- 374 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Haukeland University Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Pneumonia
- Interventions
- Ultra-rapid molecular point-of-care testing
- Participants
- 374
- Sites
- 1
- Countries
- Norway
Trials that died the same way
- Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
“The trial was stopped for futility in view of the results of the anticipated analysis” - Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
“After interim analysis the study was halted to redesign a pivotal trial.” - Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
“The trial closed early due to slow accrual.” - Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
“The results from the interim analysis were not favorable to continue this trial.” - A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults
“The trial was terminated early due to regulatory constraints preventing the continuation of study conduct.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.